Sign In
Buy HOWL
$0.362
-0.0084 (-2.27%)
At Close: Jun 23, 2026
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Tuesday, 02'nd Sep 2025
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the developmen
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 14'th Aug 2025
– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma a
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
08:00am, Wednesday, 09'th Jul 2025
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics to Participate in the BIO International Convention
08:00am, Thursday, 12'th Jun 2025
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
01:06pm, Thursday, 29'th May 2025
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
08:00am, Thursday, 29'th May 2025
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit
08:00am, Tuesday, 13'th May 2025
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 08'th May 2025
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year –
- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production -
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Monday, 05'th May 2025
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
11:06am, Friday, 25'th Apr 2025
Werewolf Therapeutics (HOWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
08:00am, Thursday, 17'th Apr 2025
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the developmen
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
08:00am, Monday, 31'st Mar 2025
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the developmen
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
07:00am, Tuesday, 11'th Mar 2025
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first ha
